GT Biopharma (NASDAQ:GTBP) Lowered to Sell Rating by Wall Street Zen

GT Biopharma (NASDAQ:GTBP) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

GT Biopharma Price Performance

GT Biopharma stock opened at $0.78 on Friday. The firm has a 50 day simple moving average of $1.42 and a 200-day simple moving average of $2.16. GT Biopharma has a 1-year low of $0.63 and a 1-year high of $4.10. The stock has a market cap of $2.78 million, a price-to-earnings ratio of -0.19 and a beta of 1.36.

GT Biopharma (NASDAQ:GTBP) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.13. Equities analysts expect that GT Biopharma will post -6.79 earnings per share for the current fiscal year.

Institutional Trading of GT Biopharma

An institutional investor recently raised its position in GT Biopharma stock. Bank of Montreal Can grew its holdings in GT Biopharma, Inc. (NASDAQ:GTBP) by 531.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,530 shares of the company’s stock after acquiring an additional 77,879 shares during the period. Bank of Montreal Can owned about 2.83% of GT Biopharma worth $331,000 as of its most recent filing with the Securities & Exchange Commission. 8.15% of the stock is owned by hedge funds and other institutional investors.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.